E Hu, K Watkins, S Groshen, S C Chen, B Malloy, R Agah, P Nichols, J Parker, A Martin, M G Boosalis
{"title":"重组白细胞介素-2和γ干扰素联合治疗晚期恶性肿瘤的I期研究。","authors":"E Hu, K Watkins, S Groshen, S C Chen, B Malloy, R Agah, P Nichols, J Parker, A Martin, M G Boosalis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.</p>","PeriodicalId":18809,"journal":{"name":"Molecular biotherapy","volume":"2 2","pages":"96-103"},"PeriodicalIF":0.0000,"publicationDate":"1990-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies.\",\"authors\":\"E Hu, K Watkins, S Groshen, S C Chen, B Malloy, R Agah, P Nichols, J Parker, A Martin, M G Boosalis\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.</p>\",\"PeriodicalId\":18809,\"journal\":{\"name\":\"Molecular biotherapy\",\"volume\":\"2 2\",\"pages\":\"96-103\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular biotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies.
A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
